Lv43
610 积分 2023-01-13 加入
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
8天前
已完结
Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo
11天前
已完结
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
12天前
已完结
Hypertrophic Cardiomyopathy–Advances in Imaging and Diagnostic Strategies
13天前
已完结
Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
15天前
已完结
Emerging treatments in hypertrophic cardiomyopathy: a focus on cardiac myosin inhibitors
21天前
已完结
Aficamten: First Approval
21天前
已完结
Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31PMYBPC3 hypertrophic cardiomyopathy cat model
25天前
已关闭
Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy
25天前
已关闭
Novel Vanilloid Receptor-1 Antagonists: 2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate
1个月前
已完结
皖公网安备34019202002308
